Vanguard Group’s Pulse Biosciences PLSE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$15.4M Buy
1,118,743
+5,052
+0.5% +$78.7K ﹤0.01% 2743
2025
Q3
$19.7M Sell
1,113,691
-110,056
-9% -$1.74M ﹤0.01% 2636
2025
Q2
$18.5M Buy
1,223,747
+380,693
+45% +$6.32M ﹤0.01% 2595
2025
Q1
$13.6M Sell
843,054
-303,285
-26% -$5.65M ﹤0.01% 2682
2024
Q4
$20M Buy
1,146,339
+150,506
+15% +$2.65M ﹤0.01% 2585
2024
Q3
$17.5M Buy
995,833
+90,446
+10% +$1.54M ﹤0.01% 2654
2024
Q2
$10.1M Buy
905,387
+58,175
+7% +$548K ﹤0.01% 2910
2024
Q1
$7.38M Buy
847,212
+189,227
+29% +$1.74M ﹤0.01% 3128
2023
Q4
$8.05M Buy
657,985
+316,519
+93% +$2.19M ﹤0.01% 3071
2023
Q3
$1.38M Buy
341,466
+51,386
+18% +$319K ﹤0.01% 3725
2023
Q2
$2.09M Sell
290,080
-278,555
-49% -$1.78M ﹤0.01% 3639
2023
Q1
$1.91M Buy
568,635
+3,861
+0.7% +$11.6K ﹤0.01% 3693
2022
Q4
$1.56M Buy
564,774
+301
+0.1% +$676 ﹤0.01% 3756
2022
Q3
$1.3M Sell
564,473
-24,291
-4% -$39.4K ﹤0.01% 3916
2022
Q2
$901K Sell
588,764
-72,655
-11% -$183K ﹤0.01% 4122
2022
Q1
$3.21M Sell
661,419
-3,623
-0.5% -$29.7K ﹤0.01% 3745
2021
Q4
$9.85M Sell
665,042
-44,813
-6% -$892K ﹤0.01% 3213
2021
Q3
$15.3M Buy
709,855
+6,407
+0.9% +$138K ﹤0.01% 2999
2021
Q2
$11.5M Buy
703,448
+47,306
+7% +$900K ﹤0.01% 3128
2021
Q1
$15.5M Buy
656,142
+16,988
+3% +$508K ﹤0.01% 2925
2020
Q4
$15.3M Sell
639,154
-699
-0.1% -$11.1K ﹤0.01% 2772
2020
Q3
$7.54M Sell
639,853
-3,689
-0.6% -$39.7K ﹤0.01% 2935
2020
Q2
$6.73M Buy
643,542
+162,150
+34% +$1.46M ﹤0.01% 2952
2020
Q1
$3.45M Sell
481,392
-603
-0.1% -$6.26K ﹤0.01% 3127
2019
Q4
$6.46M Buy
481,995
+17,728
+4% +$253K ﹤0.01% 3075
2019
Q3
$7.17M Buy
464,267
+1,073
+0.2% +$13.9K ﹤0.01% 2996
2019
Q2
$6.11M Buy
463,194
+22,800
+5% +$311K ﹤0.01% 3097
2019
Q1
$7.75M Buy
440,394
+69,209
+19% +$1.09M ﹤0.01% 2962
2018
Q4
$4.25M Buy
371,185
+36,278
+11% +$439K ﹤0.01% 3141
2018
Q3
$4.75M Buy
334,907
+77,157
+30% +$1.1M ﹤0.01% 3259
2018
Q2
$3.9M Buy
257,750
+26,372
+11% +$446K ﹤0.01% 3285
2018
Q1
$3.13M Buy
231,378
+6,738
+3% +$128K ﹤0.01% 3309
2017
Q4
$5.3M Sell
224,640
-34,645
-13% -$818K ﹤0.01% 3113
2017
Q3
$4.83M Sell
259,285
-8,525
-3% -$194K ﹤0.01% 3134
2017
Q2
$9.25M Buy
267,810
+88,902
+50% +$2.44M ﹤0.01% 2817
2017
Q1
$3.65M Buy
178,908
+139,572
+355% +$1.9M ﹤0.01% 3173
2016
Q4
$256K Buy
+39,336
New +$233K ﹤0.01% 3851

Other funds holding PLSE

Vanguard Group's PLSE Position: Q4 2025 in Review

Vanguard Group increased its Pulse Biosciences (PLSE) stake by 0.45% in Q4 2025, buying an estimated $78.7K and bringing the position to 1,118,743 shares worth $15.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2743.

Vanguard Group first reported a position in PLSE in Q4 2016 and has held it in 37 quarters since. The position peaked at $20M in Q4 2024. 82 funds tracked by Wall St. Rank hold PLSE as of Q4 2025.

  • Vanguard Group held 1,118,743 shares of Pulse Biosciences worth $15.4M as of Q4 2025.
  • Vanguard Group bought 5,052 Pulse Biosciences shares in Q4 2025, an estimated $78.7K.
  • Pulse Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2743 holding.
  • Vanguard Group first reported a position in Pulse Biosciences in Q4 2016 and has held it in 37 quarters since.
  • Vanguard Group's Pulse Biosciences position peaked at $20M in Q4 2024.
  • 82 funds tracked by Wall St. Rank held Pulse Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.